UCB secures USD1.1 B global rights for Antengene’s next-generation autoimmune therapy

CHINA—Belgian pharmaceutical company UCB has struck a major licensing agreement with Chinese biotech firm Antengene, acquiring worldwide rights to develop and commercialize ATG-201, an experimental therapy for autoimmune diseases.

The deal, announced Wednesday, includes USD60 million in upfront payments and could reach over USD1.1 billion if development and commercial milestones are achieved.

The announcement sent Antengene’s Hong Kong-listed shares climbing approximately 6% on Wednesday morning, reflecting investor confidence in the partnership.

Antengene emphasized that the agreement validates its proprietary AnTenGager platform, which the company describes as uniquely positioned in the competitive field of immune cell engagers.

How the therapy works

ATG-201 represents a new class of treatment called T-cell engagers (TCEs) that target B-cell depletion.

These therapeutic agents work by selectively eliminating B cells, which contribute to various autoimmune disorders and certain blood cancers.

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.

What sets Antengene’s approach apart is its steric masking technology, where the CD3-binding arm remains hidden until the therapy encounters its target antigen.

This design aims to improve tolerability while maintaining potent activity against diseased cells.

The therapy also incorporates bivalent CD19 binding and a proprietary CD3 sequence, features intended to enhance B-cell depletion while minimizing the risk of cytokine release syndrome, a potentially serious side effect.

Development timeline and partnership structure

Antengene plans to submit clinical trial applications in Australia and China during the first quarter of 2026.

The company will conduct initial first-in-human Phase 1 studies in both jurisdictions before handing off subsequent development responsibilities to UCB.

Under the licensing agreement, Antengene stands to receive upfront and near-term milestone payments totaling USD 80 million, with additional success-based payments potentially reaching approximately USD1.1 billion.

The company will also earn tiered royalties based on future net sales, though specific financial details remain undisclosed.

Strategic significance

UCB’s Chief Scientific Officer Alistair Henry described T-cell engagers as an emerging and potentially disruptive therapeutic modality for immunological diseases.

He noted that accessing Antengene’s platform technology strengthens UCB’s position in immunology, complementing its existing expertise in monoclonal antibodies and novel biologics while advancing the company into bispecific T-cell engager development.

Dr. Jay Mei, Antengene’s Founder, Chairman, and CEO, expressed enthusiasm about combining his company’s discovery platform with UCB’s deep immunology expertise to accelerate global development of ATG-201.